Heart failure remains a leading cause of morbidity and mortality worldwide. Although depressed pump function is common, development of effective therapies to stimulate contraction has proven difficult. This is thought to be attributable to their frequent reliance on cAMP stimulation to increase activator Ca 2ϩ . A potential alternative is nitroxyl (HNO), the 1-electron reduction product of nitric oxide (NO) that improves contraction and relaxation in normal and failing hearts in vivo. The mechanism for myocyte effects remains unknown. Here, we show that this activity results from a direct interaction of HNO with the sarcoplasmic reticulum Ca 2ϩ pump and the ryanodine receptor 2, leading to increased Ca 2ϩ uptake and release from the sarcoplasmic reticulum. HNO increases the open probability of isolated ryanodine-sensitive Ca 2ϩ -release channels and accelerates Ca 2ϩ reuptake into isolated sarcoplasmic reticulum by stimulating ATP-dependent Ca 2ϩ transport. Contraction improves with no net rise in diastolic calcium. These changes are not induced by NO, are fully reversible by addition of reducing agents (redox sensitive), and independent of both cAMP/protein kinase A and cGMP/protein kinase G signaling. Rather, the data support HNO/thiolate interactions that enhance the activity of intracellular Ca 2ϩ cycling proteins. These findings suggest HNO donors are attractive candidates for the pharmacological treatment of heart failure. (Circ Res. 2007;100:96-104.) 
C ongestive heart failure affects an estimated 5 million people in the United States and has an annual mortality rate approaching 20%. More than half of the patients have depressed cardiac function, and, although improvement in function is clearly beneficial, as revealed by heart transplantation, development of effective pharmacological therapy to safely stimulate contraction has proven problematic. 1 Most such agents rely on enhancing cAMP and protein kinase A (PKA) to stimulate activator Ca 2ϩ and increase contractility. However, this approach is less effective in failing hearts, because of downregulation of the signaling, 2 and is chronically linked to toxicity and increased mortality.
We recently reported that donors of nitroxyl (HNO), the 1-electron reduction product of nitric oxide (NO), 3 have novel cardiovascular effects quite different from NO. In intact in vivo hearts, the HNO donor Angeli's salt (AS) enhances function independent of ␤-adrenergic blockade or stimulation and unaccompanied by changes in cGMP. 4, 5 Unlike most prior positive inotropes, HNO donors are similarly effective in normal and failing hearts. 5 Their combined ability to enhance heart function, while reducing venous pressures, has suggested potential utility as a heart failure treatment.
The mechanisms underlying cardiac action of HNO remain unknown. HNO can stimulate ion channels such as the N-methyl-D-aspartate receptor. 6, 7 Recent data suggest that it also activates the skeletal muscle ryanodine receptor (RyR). 8 HNO is thought to react with targeted thiols 9 and, more specifically, negatively charged thiols, or thiolates. These exist in several proteins involved in Ca 2ϩ cycling, such as the sarcoplasmic reticular (SR) Ca 2ϩ release channel, 10 SR Ca 2ϩ pump (sarcoplasmic reticulum Ca 2ϩ -ATPase [SERCA2a]), and possibly phospholamban. 11 Hence, we hypothesized that HNO activity targets heart muscle cells and directly improves contraction and relaxation by enhancing Ca 2ϩ cycling. Our results support improvement in SR Ca 2ϩ uptake and release that is independent of cAMP/PKA or cGMP/PKG but, rather, related to thiol modification.
Materials and Methods
Reagents AS (Na 2 N 2 O 3 ) was a generous gift of Dr Jon M. Fukuto and Matthew I. Jackson (University of California, Los Angeles). AS (100 mmol/L) stock solution was freshly prepared by dissolving AS in 10 mmol/L NaOH. Sodium-2-(N,N-diethylamino)-diazenolate-2-oxide (DEA/ NO) was purchased from Calbiochem (San Diego, Calif). Indo 1 acetoxymethyl ester (Indo 1-AM) was purchased from Molecular Probes/Invitrogen (Carlsbad, Calif). 1H- [1, 2, 4] Oxadiazolo quinoxalin 1-one (ODQ) was obtained from Tocris (Ellisville, Mo). All other compounds were purchased from Sigma Chemical Co (St Louis, Mo; Milan, Italy).
Contraction and Whole Ca 2؉ Transients in Mouse Ventricular Myocytes and Whole Ca 2؉ Transients and SR Ca 2؉ Load in Rat Ventricular Myocytes
Wild-type 2-to 4-month-old mice were anesthetized with intraperitoneal pentobarbital sodium (100 mg/kg IP). Heart perfusion and isolation of rat ventricular myocytes were performed as described 12 (see the online data supplement, available at http://circres.ahajournals. org). Functional measurements are described in the online data supplement. The protocols were all approved by the Animal Care and Use Committee of Johns Hopkins University.
FRET Imaging
Primary cultures of cardiac ventricular myocytes from 1-to 3-dayold Sprague-Dawley rats (Charles River Laboratories, Wilmington, Mass) were prepared according to Dostal et al. 13 FRET analysis was performed as described 14 (see online data supplement).
Fluorescent Probes for Two-Photon Laser Scanning Microscopy and Image Acquisition
The cationic potentiometric fluorescent dye tetramethylrhodamine methyl ester (TMRM) was used to monitor changes in ⌬⌿ m , as previously described. 15 The production of the fluorescent glutathione adduct GSB from the reaction of cell permeant monochlorobimane (MCB) with reduced glutathione (GSH), catalyzed by glutathione S-transferase, was used to measure intracellular glutathione levels. Details of GSH measurements are provided in the online data supplement.
Visualization of Spontaneous Ca 2؉ Sparks and Measurement of Spark Frequency
Isolated mouse cardiac myocytes were loaded with the Ca 2ϩ indicator fluo-4 acetoxymethyl ester (fluo-4/AM) (Molecular Probes, 20 mol/L for 30 minutes). Confocal images were acquired using a confocal laser-scanning microscope (LSM510, Carl Zeiss) with a Zeiss Plan-Neofluor ϫ40 oil immersion objective (NAϭ1.3). Fluo-4/AM was excited by an argon laser (488 nm), and fluorescence was measured at Ͼ505 nm. Images were taken in the line-scan mode, with the scan line parallel to the long axis of the myocytes. Each image consisted of 512 line scans obtained at 1.92-ms intervals, each comprising 512 pixels at 0.10-m separation. Digital image analysis used customer-designed programs coded in interactive data language and a modified spark detection algorithm. 16
RyR2 Single-Channel Recordings in Planar Lipid Bilayers
Recording of single RyR2 in lipid bilayers was performed as described 17 (see the online data supplement).
Measurements of ATP-Dependent Ca 2؉ Uptake by Murine Cardiac SR Vesicles
Crude cardiac microsomal vesicles containing fragmented SR were prepared as described 18 (see also the online data supplement). SR membrane vesicles (0.4 mg/mL) suspended in a medium containing 100 mmol/L KCl, 1 mmol/L MgCl 2 , 50 mol/L arsenazo III, 5 mmol/L sodium azide, and 20 mmol/L MOPS, pH 7.4, were mixed with an equal volume of an identical medium containing 1 mmol/L Na 2 ATP at 24°C in a manually operated stopped-flow apparatus (Applied Photophysics Ltd). The total [Ca 2ϩ ] in the uptake medium was 0.5 mol/L, yielding a free [Ca 2ϩ ] in equilibrium with the Ca/arsenazo III complex of 0.2 mol/L (K A ϭ3.3ϫ10 4 mol/L Ϫ1 ). The change in [Ca 2ϩ ] was monitored at 0.1-second intervals using a single-beam UV-VIS spectrophotometer (AVIV, Model 14DS) with a monochromator setting of 650 nm. The signal change caused by vesicle light scattering was evaluated from separate measurements conducted under identical conditions at the isosbestic wavelength of 693 nm (red-shifted from 685 nm by the presence of protein). Addition of AS (250 mol/L) to the incubation medium had no effect on the spectral characteristics of arsenazo III or its response to Ca 2ϩ . The kinetic and thermodynamic parameters for Ca 2ϩ uptake were evaluated by fitting stopped-flow signals to 1-and 2-exponential decay functions plus a residual term using nonlinear regression. Residual plots of the difference between the fitted curve and data points were used to evaluate systematic errors in the fits and to calculate the sum-of-squares error used in selecting the best fit.
Results
To test whether HNO directly influences myocyte function, freshly isolated adult mouse myocytes (C57/Bl6) were exposed to AS (10 Ϫ6 to 10 Ϫ3 mol/L), matching concentrations relevant in vivo. 4, 5 Myocyte contractility rose in a dosedependent manner ( Figure 1A and 1B), peaking at Ϸ100% at 0.5 and 1 mmol/L (both PϽ0.00005). Myocyte relaxation rate also improved by 10% to 20% ( Figure 1C ; PϽ0.05). These changes plateaued after Ϸ10 to 15 minutes and were reversible (at Յ500 mol/L) 15 minutes after stopping exposure to AS ( Figure 1A) . In contrast to HNO, the NO donor DEA/NO induced slight functional depression at low doses and minimal changes at higher doses ( Figure 1B) .
At physiological pH, AS decomposes into HNO and nitrite. We therefore tested whether nitrite might contribute to the observed response. AS decomposition in the identical medium and temperature as used in the myocyte studies yielded 25% nitrite generation after Ϸ1000 seconds (16 minutes). Identical results were obtained with 0.1 to 1 mmol/L AS. This meant that at the time of functional analysis, 25 to 250 mol/L NO 2 Ϫ was expected. However, direct exposure to such levels of NO 2 Ϫ (and higher and lower doses) had no effect on sarcomere shortening.
Agents that concomitantly increase myocyte contraction and accelerate relaxation are often linked to a rise in intracellular cAMP and subsequent activation of PKA. 19 To test whether this applied to AS/HNO, we performed real-time imaging of cAMP on neonatal rat cardiomyocytes transfected with a cAMP FRET probe. 14 On exposure to 1 mmol/L AS, the FRET signal was unchanged (0.3%Ϯ0.1%; nϭ23; PϭNS), whereas subsequent application of norepinephrine (10 mol/L) or phosphodiesterase inhibitor 3-isobutyl-1methylxanthine (100 mol/L) both increased it by 12% (PϽ10 Ϫ6 ) ( Figure 2A ). Pretreatment of adult mouse myocytes with the PKA inhibitor Rp-CPT-cAMPs (100 mol/L; Figure  2B ) did not alter HNO-enhanced sarcomere shortening.
AS/HNO-stimulated contractility was also independent of cGMP/PKG. Preincubation with the soluble guanylate cyclase inhibitor ODQ (10 mol/Lϫ30 minutes) prevented DEA/NO-induced negative inotropy but had no impact on AS/HNO inotropy. Pretreatment with a PKG inhibitor (Rp-8Br-cGMPs, 10 mol/L) prevented DEA/NO negative inotropy, converting it to a modest positive response, yet had no impact on AS/HNO inotropy ( Figure 2C) .
NO donors exert a negative effect on ␤-adrenergic stimulation in vitro and in vivo 20 ; however, we previously found the opposite for HNO donors in intact hearts. 5 We confirmed this in cardiomyocytes. Cells challenged with isoproterenol (ISO) (2.5 nmol/L) had a 100Ϯ27% increase in sarcomere shortening (Pϭ0.002, nϭ30). This was markedly blunted by coinfusion of 0.25 mmol/L DEA/NO, whereas coapplication of 0.5 mmol/L AS/HNO doubled shortening above ISO alone ( Figure 2D ). Thus, AS/HNO acts in parallel with the ␤-adrenergic pathway.
HNO targets thiol groups on selective proteins. 9 To test whether such interaction could underlie whole cell contractile effects, studies were performed in which myocyte thiol equivalents were first enhanced using a cell-permeable esterderivative of GSH (GSH ethyl ester in Tyrode's solution, 4 mmol/L for 3 hours). We hypothesized that by enriching the intracellular thiol content, the probability of trapping HNO before it targeted critical thiol residues related to excitation/ contraction coupling would be enhanced. Pretreatment with GSH enhanced intracellular thiol equivalents (ϩ6Ϯ1.5% in fluorescence arbitrary units versus controls, nϭ40, PϽ0.05) determined by fluorescence assay of GSH S-bimane production using 2-photon microscopy. Pretreated cells were then exposed to AS/HNO (0.5 mmol/L), and the contractility response was substantially blunted (ϩ57Ϯ19%; Pϭ0.02 versus base; Pϭ0.05 versus AS alone) ( Figure 2E ). This supports the targeting of HNO on SH groups to exert its cardiotropic action.
Next, we examined Ca 2ϩ cycling in adult mouse and rat cardiac myocytes. Cells were first exposed to AS/HNO for 5 to 10 minutes, then washed and loaded with Indo-1 or fluo-4 for 20 minutes. Pretreatment with AS was necessary because the drug reacted with the Ca 2ϩ indicators (both fluo-4 and Indo-1) and altered their fluorescent properties. In mice, the Ca 2ϩ transient amplitude assessed by confocal line-scan imaging increased by Ϸ40% over baseline with 0.5 mmol/L AS (nϭ27, PϽ0.001) ( Figure 3A and 3B) , and time to peak transient was prolonged ( Figure 3C) , whereas the decay time shortened ( Figure 3D ). Basal fluorescence (F 0 ) was unchanged by AS pretreatment ( Figure 3E ). Similar results were obtained in rat myocytes (using Indo-1) for Ca 2ϩ transient amplitude (Figure 4A and 4B) and decay time ( Figure 4C ). The increase in amplitude was not accompanied by an increase in diastolic Ca 2ϩ level (ratio 405/485ϭ0.239Ϯ0.006
[control] versus 0.243Ϯ0.008 [AS]; PϭNS; see also Figure  3A and 3E and Figure 4A ). Rapid sustained caffeine (10 mmol/L) application abruptly releases all SR Ca 2ϩ and subsequent [Ca 2ϩ ] i decline is mediated mainly via Na/Ca exchange (NCX). The amplitude and tau of decline of the caffeine-induced Ca 2ϩ transient indicates that HNO did not alter SR Ca 2ϩ content ( Figure 4F ) or NCX function (ϭ2.0Ϯ0.4 versus 2.2Ϯ0.3 seconds; Figure 4E ). These results indicate that the HNO-enhanced [Ca 2ϩ ] i decline was attributable to increased SERCA2a function, and the HNOenhanced Ca 2ϩ transient amplitude was caused by enhanced fractional SR Ca 2ϩ release ( Figure 4D ) with unaltered SR Ca 2ϩ content ( Figure 4F ). Given evidence for enhanced SR Ca 2ϩ reuptake and release, with no net gain in total SR Ca 2ϩ content, we next examined direct effects of AS/HNO on the ryanodinesensitive release channel (RyR2). In intact myocytes, AS enhanced RyR2 opening probability, as revealed by an increased frequency of Ca 2ϩ sparks assessed by line-scan confocal microscopy ( Figure 5A ), in a dose-dependent manner ( Figure 5B ; 18-fold rise in spark frequency at 1 mmol/L AS, nϭ10 to 24, PϽ0.001). Conversely, DEA/NO had no effect on spark generation ( Figure 5C ). Individual spark amplitude, rise time, and spatial width were unaltered by AS, indicating a primary effect on RyR2 activation. SR Ca 2ϩ store depletion by thapsigargin (10 mol/L, 30 minutes) or ryanodine exposure (10 mol/L) abolished Ca 2ϩ sparks in control and AS (0.5 mmol/L, data not shown). The influence of AS/HNO on Ca 2ϩ sparks was thiol sensitive. Preincubating cells with reduced glutathione (4 mmol/L for 3 hours) before AS exposure prevented increased spark frequency ( Figure  5D ), indicating that increased intracellular thiol content effectively quenched HNO action.
To further test whether HNO directly interacted with RyR2 proteins to increase open probability, purified reconstituted RyR2 were expressed in planar lipid bilayers and steady-state activity recorded with or without AS/HNO. The cis (cytosolic) solution contained 10 mol/L activating Ca 2ϩ , and recordings were made at positive 30-mV holding potential. AS (0.1 to 1 mmol/L) produced a dose-dependent rapid increase in frequency and the mean time of open events without altering unitary channel conductance ( Figure 5E ). The probability of the channel being open (P o ) increased from an average 0.16Ϯ0.03 without AS/HNO to 0.46Ϯ0.07 at 0.3 mmol/L AS added to the cytoplasmic side of the channel (nϭ4). This was reversible on addition of 2 mmol/L dithiothreitol (0.11Ϯ0.04). These findings support direct HNO/ RyR2 interaction likely via a reversible reaction with thiol groups in the protein.
We investigated whether HNO directly enhances SR Ca 2ϩ uptake by studying its effects on SR membrane vesicles isolated from pooled mouse hearts. Crude SR microsomal vesicles were incubated with 250 mol/L AS before measuring ATP-dependent Ca 2ϩ uptake by stopped-flow mixing at 24°C. Arsenazo III was used to monitor Ca 2ϩ removal from the extravesicular compartment and buffer the free [Ca 2ϩ ] at a level producing half-saturation of the Ca 2ϩ pump (Ϸ0.2 mol/L). The time course of Ca 2ϩ accumulation monitored at 650 nm was biphasic ( Figure 6A ), likely reflecting different vesicle populations associated with the light and heavy fractions of SR. 21 Incubation with 250 mol/L AS for 15 minutes increased the activity of the fast (0.047 versus 0.64 sec Ϫ1 ; PϽ0.05) and the slow (0.069 versus 0.136 sec Ϫ1 ; PϽ0.0005; nϭ6) uptake phases ( Figure  6B ; Table) , without affecting total Ca 2ϩ uptake (Table) . Ca 2ϩ uptake activity was abolished by preincubation with 10 mol/L thapsigargin (not shown), whereas exposure to the Ca 2ϩ ionophore A23187 (5 g/mg SR protein) diminished total Ca 2ϩ uptake by Ϸ50% ( Figure 6E ). Stopped-flow signals acquired at the isosbestic wavelength of 693 nm were also biphasic ( Figure 6C and 6D) . The decrease in absorbance at 693 nm, representing scattered light associated with Ca 2ϩ sequestration and osmotic vesicle swelling, was subtracted from the 650 nm signal before analysis. After subtraction, Ca 2ϩ accumulation exhibited a monophasic time course with Ͼ90% of uptake occurring within the initial 20s ( Figure 6F and 6G).
AS/HNO exposure increased the rate constant for Ca 2ϩ uptake by 104% based on exponential analysis of the 650 to 693 nm signal (0.1563 versus 0.3204 sec Ϫ1 ; PϽ0.0005; nϭ6) ( Figure 6H, left) . The difference between total Ca 2ϩ uptake at equilibrium before and after exposure to AS/HNO was not Figure 5 ).
Discussion
In the physiological setting, cardiac contractile force and rate of force decay are enhanced via cAMP/PKA-coupled mechanisms that trigger activator Ca 2ϩ to stimulate the myofilaments and SR uptake to hasten relaxation. Yet, altered cAMP/PKA signaling can contribute to chronic remodeling and failure. Therapies mimicking these pathways have generally proven ineffective for long-term treatment of cardiac failure. Here we reveal that HNO acts very differently on the heart muscle cell, augmenting contractility and accelerating relaxation, independent of cAMP/PKA, by enhancing the Ca 2ϩ transient by increasing both SR Ca 2ϩ uptake and release. These 2 counterbalancing effects likely explain why diastolic Ca 2ϩ does not rise and total SR Ca 2ϩ load remains unchanged. Moreover, this direct effect is redox sensitive and reversible and is very different to the effects produced by NO.
Increased SR Ca 2ϩ release with unaltered total SR Ca 2ϩ content suggests HNO modifies RyR2 function rather than induces a leak by increasing intra-SR Ca 2ϩ stores. 22 These effects are quite different from that exerted by NO donors, ␤ agonists, and caffeine. NO donors are reported to enhance 23, 24 or inhibit RyR2, 25 but not alter basal Ca 2ϩ spark frequency. 26 ␤ Agonists stimulate RyR2 open probability via PKAmediated phosphorylation, 27 and Ca 2ϩ spark frequency can increase by this mechanism and further by phosphorylation of phospholamban, which enhances SR Ca 2ϩ load. 28 In transgenic mice overexpressing human ␤ 2 receptors, Ca 2ϩ sparks are larger and more frequent than in nontransgenic cells, despite having resting cytosolic Ca 2ϩ and Ca 2ϩ SR load similar to controls. 28 This suggests that ␤-mediated cAMP-PKA activation alters not only RyR2 sensitivity to Ca 2ϩ but also Ca 2ϩ release-linked RyR2 inactivation, 29 potentially changing SR stability. In contrast, HNO increases spark frequency without altering individual spark characteristics or adversely impacting Ca 2ϩ stability. The action of HNO on RyR2 is also different from that of caffeine, which increases the frequency of spontaneous Ca 2ϩ -release events (Ca 2ϩ waves), an effect that persists even after discontinuing the drug, 30 leading to a substantial decrease in SR Ca 2ϩ content.
The unique action of HNO on RyR2 may relate to its thiophilic chemistry. 3, 9 HNO effects were rapidly reversed by reducing equivalents, suggesting real-time competition for HNO between free thiols and critical thiol residues on the RyR2. The data showing that a 6% increase in intracellular GSH blunts 57% of HNO effects on sarcomere shortening suggests HNO targets selective thiolate residues rather than having a generalized interaction. 9 Identification of these specific targets awaits subproteome analysis of cysteine modification, with site mutagenesis, to confirm the functional importance of particular targets. Selective thiophilic action of HNO 3 might suggest that it is an in vivo signaling molecule, 31, 32 although this remains speculative as methods to measure in vivo synthesis are currently unavailable.
To sustain cardiac inotropy in the presence of HNOinduced increase in the fractional release of Ca 2ϩ from RyR2, the velocity of Ca 2ϩ reuptake into the SR should increase Figure 6 . HNO increases ATP-dependent Ca 2ϩ uptake in murine sarcoplasmic reticulum (SR) vesicles. A and B, Representative stopped-flow recordings of active Ca 2ϩ accumulation monitored by arsenazo III at 650 nm in the absence (ϪAS) and presence (ϩAS) of 250 mol/L AS. The downward deflection of the signal represents Ca 2ϩ uptake from the extravesicular medium. The initial absorbance reading on the y-axis was normalized to 0 by subtracting the absorbance at tϭ0 from each of the absorbance readings. The solid curve through the data points represents the best fit of the data to a biexponential plus residual equation. C and D, Representative changes in light-scattering measured by stopped-flow mixing at the isosbestic wavelength of 693 nm in the absence (ϪAS) and presence (ϩAS) of 250 mol/L AS. Reaction conditions were identical to those in A and B above. E, Representative stopped-flow recordings of active Ca 2ϩ accumulation monitored at 650 nm in the absence (control) and presence of the Ca 2ϩ ionophore (A23187). F and G, Representative time course of active Ca 2ϩ uptake in SR vesicles determined by subtraction of a stopped-flow trace acquired at 693 nm from a trace acquired at 650 nm (⌬Abs 650 nmϪ⌬Abs 693 nm). The traces were normalized as described above before subtraction. H, Effect of AS/HNO on (left) Ca 2ϩ uptake activity (sec Ϫ1 ) and (right) total Ca 2ϩ uptake evaluated from the 650 to 693 nm signal. during relaxation. 33 This latter process is slowed in the failing heart, and recent efforts to stimulate it by gene modulation (eg, manipulation of phospholamban 34, 35 or increased SERCA2a expression 36 ) highlight the therapeutic attractiveness of this target. AS/HNO stimulated Ca 2ϩ uptake in both myocytes and isolated cardiac SR, supporting direct action on SERCA2a. The mechanism remains unknown but could involve direct targeting of SERCA2a by HNO, or releasing some of the inhibition of SERCA2a by phospholamban. 37 Although we did not assess whether HNO alters the phosphorylation of various EC coupling proteins (eg, RyR2, phospholamban) as a mechanism for inotropy, several lines of evidence suggests such changes are unlikely and/or separate from HNO modulation. First, both PKG and PKA blockade had no effect on HNO inotropy. Second, HNO did not alter cAMP. Third, HNO effects were rapidly reversible by adding thiolreducing agents, which would not be observed if a primary phosphorylation mechanism was involved. Fourth, the RyR2 studies were performed in reconstituted membranes without kinases to stimulate phosphorylation, and the responses in this preparation were highly concordant with those observed by Ca 2ϩ sparks in intact cells. Lastly, HNO inotropic response in myocytes was shown to be additive to ␤ agonists, suggesting that HNO and ␤-adrenergic pathways act in parallel.
Our data provide important new insights into our prior intact animal studies 4,5 that first revealed HNO donors improve function in the failing heart, independent of ␤-adrenergic blockade, and additive to ␤-adrenergic agonists. Initial studies had first suggested a possible role of HNO in stimulating calcitonin gene-related peptide (CGRP) release 4 ; however, subsequent studies confirmed this effect was sympathostimulatory, inhibited by ␤ blockers, and not mediated by direct myocyte CGRP effects. 38 The current data reveal a direct enhancement of myocyte Ca 2ϩ cycling. However, changes in Ca 2ϩ handling are not the sole mechanisms as other recent data from our laboratory have found AS/HNO also enhances maximal Ca 2ϩ -activated force without altering diastolic Ca 2ϩ levels in isolated rat trabeculae. Thus, HNO also acts as a myofilament Ca 2ϩ sensitizer at systolic Ca 2ϩ levels (T. Dai, Y. Tian, C. G. Tocchetti, T. Katori, D. A. Kass, N. Paolocci, W. Gao, manuscript submitted for publication). This factor would appear to work in concert with increased Ca 2ϩ cycling revealed in the current study.
Several study limitations should be noted. First, cells from healthy hearts were studied, and the observed effects of HNO may not directly translate to myocytes from failing ventricles. However, in prior in vivo studies, we observed a similar efficacy of HNO on cardiac function in normal and failing hearts. 5 Second, we did not examine the coupling between L-type calcium current and RyR2 activation (coupling gain), or determine whether the L-type current itself is altered by HNO. However, enhanced SR calcium uptake and release was demonstrated in isolated SR and reconstituted RyR2, where the gain interaction would not be relevant. Regarding the latter, the lack of change in Ca 2ϩ extruded by the NCX and in total SR Ca 2ϩ content suggests L-type Ca 2ϩ current was unlikely to be altered.
The present data suggest an intriguing potential for the use of HNO donors to treat depressed heart function, particularly in light of prior work confirming efficacy in intact large animals with heart failure. Although an agent that increased SR Ca 2ϩ release might raise concerns of proarrhythmia, 39 the manner by which HNO achieves this effect is novel, and thus its consequences may be as well. Importantly, the current data show increased Ca 2ϩ fractional release counterbalanced by improved uptake so that SR Ca 2ϩ load and diastolic Ca 2ϩ levels are unchanged.
Future studies examining HNO responses in myocytes from failing hearts, longer-term exposure studies, and, ultimately, clinical studies will be needed to prove HNO efficacy and safety for the treatment of decompensated hearts, but the present data provide a valuable starting point for such investigations.
